NeuroPace ( (NPCE) ) has provided an announcement.
On April 14, 2025, NeuroPace announced that it expects minimal impact from international trade tariffs on its operations and financial results, reaffirming its gross margin guidance for 2025. The company, which primarily manufactures and sells its devices in the U.S., anticipates no significant effect on its gross margin despite terminating its SEEG distribution agreement with DIXI Medical effective October 1, 2025. NeuroPace will report its first quarter 2025 financial results on May 13, 2025, with a conference call scheduled for the same day.
Spark’s Take on NPCE Stock
According to Spark, TipRanks’ AI Analyst, NPCE is a Neutral.
NeuroPace exhibits significant revenue growth and strategic initiatives, which bolster its potential. However, high debt levels and negative cash flows pose substantial risks. The technical outlook is positive, yet valuation concerns due to negative earnings persist.
To see Spark’s full report on NPCE stock, click here.
More about NeuroPace
NeuroPace, Inc., based in Mountain View, California, is a medical device company dedicated to improving the lives of people with epilepsy. The company offers the RNS System, a brain-responsive platform that provides personalized, real-time treatment for seizures, aiming to enhance the standard of care for patients with drug-resistant epilepsy and potentially other brain disorders.
YTD Price Performance: -10.02%
Average Trading Volume: 249,409
Technical Sentiment Signal: Hold
Current Market Cap: $339.3M
See more data about NPCE stock on TipRanks’ Stock Analysis page.